This new therapy, which was approved by the US Food and Drug Administration in March 2022, uses a tracing agent (ligand) that attaches to PSMA, a protein on the surface of most prostate cancer cells. If this tracer binds to the cancer cells, they light up on a PET/CT scan and patients are then eligible for a drug called Pluvicto™, which is then injected into the bloodstream to deliver targeted radiation to cancer cells throughout the body that express PSMA. The treatment targets bone, nodal and visceral metastases.
Adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:
“With this new treatment, we’re seeing significant improvement in progression-free survival. Patients are living longer and better, usually with no significant side effects. I’m thrilled that Virginia Cancer Specialists is able to provide this option for patients in our community.”
Gregory Sibley, MD, Radiation Oncology, Virginia Cancer Specialists
Pluvictotm helped Men Live Longer: Men with PSMA+ mCRPC who received PluvictoTM plus the best standard of care lived a median of 4 months longer: 15.3 months vs. 11.3 months with BSoC (best standard of care) alone.*
Time without progression: Men treated with Pluvictotm plus BSoC lived longer without their cancer growing or spreading – a median of 8.7 months compared with 3.4 months when on BSoC only.**